These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24144360)

  • 1. Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase.
    Cummings MD; Lin TI; Hu L; Tahri A; McGowan D; Amssoms K; Last S; Devogelaere B; Rouan MC; Vijgen L; Berke JM; Dehertogh P; Fransen E; Cleiren E; van der Helm L; Fanning G; Nyanguile O; Simmen K; Van Remoortere P; Raboisson P; Vendeville S
    J Med Chem; 2014 Mar; 57(5):1880-92. PubMed ID: 24144360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055.
    Vendeville S; Lin TI; Hu L; Tahri A; McGowan D; Cummings MD; Amssoms K; Canard M; Last S; Van den Steen I; Devogelaere B; Rouan MC; Vijgen L; Berke JM; Dehertogh P; Fransen E; Cleiren E; van der Helm L; Fanning G; Van Emelen K; Nyanguile O; Simmen K; Raboisson P
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4437-43. PubMed ID: 22633687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modeling study on the drug resistance mechanism of NS5B polymerase to TMC647055.
    Wang H; Cui W; Guo C; Chen BZ; Ji M
    Biochem Cell Biol; 2016 Apr; 94(2):147-58. PubMed ID: 26836778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage.
    Devogelaere B; Berke JM; Vijgen L; Dehertogh P; Fransen E; Cleiren E; van der Helm L; Nyanguile O; Tahri A; Amssoms K; Lenz O; Cummings MD; Clayton RF; Vendeville S; Raboisson P; Simmen KA; Fanning GC; Lin TI
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4676-84. PubMed ID: 22710121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase.
    Gentles RG; Ding M; Bender JA; Bergstrom CP; Grant-Young K; Hewawasam P; Hudyma T; Martin S; Nickel A; Regueiro-Ren A; Tu Y; Yang Z; Yeung KS; Zheng X; Chao S; Sun JH; Beno BR; Camac DM; Chang CH; Gao M; Morin PE; Sheriff S; Tredup J; Wan J; Witmer MR; Xie D; Hanumegowda U; Knipe J; Mosure K; Santone KS; Parker DD; Zhuo X; Lemm J; Liu M; Pelosi L; Rigat K; Voss S; Wang Y; Wang YK; Colonno RJ; Gao M; Roberts SB; Gao Q; Ng A; Meanwell NA; Kadow JF
    J Med Chem; 2014 Mar; 57(5):1855-79. PubMed ID: 24397558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of N-[4-[6-tert-butyl-5-methoxy-8-(6-methoxy-2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a potent inhibitor of the hepatitis C virus NS5B polymerase.
    Talamas FX; Abbot SC; Anand S; Brameld KA; Carter DS; Chen J; Davis D; de Vicente J; Fung AD; Gong L; Harris SF; Inbar P; Labadie SS; Lee EK; Lemoine R; Le Pogam S; Leveque V; Li J; McIntosh J; Nájera I; Park J; Railkar A; Rajyaguru S; Sangi M; Schoenfeld RC; Staben LR; Tan Y; Taygerly JP; Villaseñor AG; Weller PE
    J Med Chem; 2014 Mar; 57(5):1914-31. PubMed ID: 24195700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi
    Taylor JG; Zipfel S; Ramey K; Vivian R; Schrier A; Karki KK; Katana A; Kato D; Kobayashi T; Martinez R; Sangi M; Siegel D; Tran CV; Yang ZY; Zablocki J; Yang CY; Wang Y; Wang K; Chan K; Barauskas O; Cheng G; Jin D; Schultz BE; Appleby T; Villaseñor AG; Link JO
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2428-2436. PubMed ID: 31133531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent macrocyclic HCV NS5A inhibitors.
    Yu W; Vibulbhan B; Rosenblum SB; Martin GS; Vellekoop AS; Holst CL; Coburn CA; Wong M; Selyutin O; Ji T; Zhong B; Hu B; Chen L; Dwyer MP; Jiang Y; Nair AG; Tong L; Zeng Q; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Fells J; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3793-9. PubMed ID: 27282743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor.
    Rosenquist Å; Samuelsson B; Johansson PO; Cummings MD; Lenz O; Raboisson P; Simmen K; Vendeville S; de Kock H; Nilsson M; Horvath A; Kalmeijer R; de la Rosa G; Beumont-Mauviel M
    J Med Chem; 2014 Mar; 57(5):1673-93. PubMed ID: 24446688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series.
    McGowan D; Vendeville S; Lin TI; Tahri A; Hu L; Cummings MD; Amssoms K; Berke JM; Canard M; Cleiren E; Dehertogh P; Last S; Fransen E; Van Der Helm E; Van den Steen I; Vijgen L; Rouan MC; Fanning G; Nyanguile O; Van Emelen K; Simmen K; Raboisson P
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4431-6. PubMed ID: 22542193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase.
    Chen KX; Vibulbhan B; Yang W; Sannigrahi M; Velazquez F; Chan TY; Venkatraman S; Anilkumar GN; Zeng Q; Bennet F; Jiang Y; Lesburg CA; Duca J; Pinto P; Gavalas S; Huang Y; Wu W; Selyutin O; Agrawal S; Feld B; Huang HC; Li C; Cheng KC; Shih NY; Kozlowski JA; Rosenblum SB; Njoroge FG
    J Med Chem; 2012 Jan; 55(2):754-65. PubMed ID: 22148957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
    Lenz O; Verbinnen T; Lin TI; Vijgen L; Cummings MD; Lindberg J; Berke JM; Dehertogh P; Fransen E; Scholliers A; Vermeiren K; Ivens T; Raboisson P; Edlund M; Storm S; Vrang L; de Kock H; Fanning GC; Simmen KA
    Antimicrob Agents Chemother; 2010 May; 54(5):1878-87. PubMed ID: 20176898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.
    Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer M; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1954-1957. PubMed ID: 29653894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons.
    Belema M; Nguyen VN; Romine JL; St Laurent DR; Lopez OD; Goodrich JT; Nower PT; O'Boyle DR; Lemm JA; Fridell RA; Gao M; Fang H; Krause RG; Wang YK; Oliver AJ; Good AC; Knipe JO; Meanwell NA; Snyder LB
    J Med Chem; 2014 Mar; 57(5):1995-2012. PubMed ID: 24437689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors.
    Ikegashira K; Oka T; Hirashima S; Noji S; Yamanaka H; Hara Y; Adachi T; Tsuruha J; Doi S; Hase Y; Noguchi T; Ando I; Ogura N; Ikeda S; Hashimoto H
    J Med Chem; 2006 Nov; 49(24):6950-3. PubMed ID: 17125247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi
    Link JO; Taylor JG; Trejo-Martin A; Kato D; Katana AA; Krygowski ES; Yang ZY; Zipfel S; Cottell JJ; Bacon EM; Tran CV; Yang CY; Wang Y; Wang KW; Zhao G; Cheng G; Tian Y; Gong R; Lee YJ; Yu M; Gorman E; Mogalian E; Perry JK
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2415-2427. PubMed ID: 31230974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency.
    Beaulieu PL; Bös M; Bousquet Y; DeRoy P; Fazal G; Gauthier J; Gillard J; Goulet S; McKercher G; Poupart MA; Valois S; Kukolj G
    Bioorg Med Chem Lett; 2004 Feb; 14(4):967-71. PubMed ID: 15013003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.
    Zhang X; Zhang N; Chen G; Turpoff A; Ren H; Takasugi J; Morrill C; Zhu J; Li C; Lennox W; Paget S; Liu Y; Almstead N; Njoroge FG; Gu Z; Komatsu T; Clausen V; Espiritu C; Graci J; Colacino J; Lahser F; Risher N; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3947-53. PubMed ID: 23683597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.
    Schoenfeld RC; Bourdet DL; Brameld KA; Chin E; de Vicente J; Fung A; Harris SF; Lee EK; Le Pogam S; Leveque V; Li J; Lui AS; Najera I; Rajyaguru S; Sangi M; Steiner S; Talamas FX; Taygerly JP; Zhao J
    J Med Chem; 2013 Oct; 56(20):8163-82. PubMed ID: 24069953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery and structure-activity relationships of pyrano[3,4-b]indole based inhibitors of hepatitis C virus NS5B polymerase.
    LaPorte MG; Draper TL; Miller LE; Blackledge CW; Leister LK; Amparo E; Hussey AR; Young DC; Chunduru SK; Benetatos CA; Rhodes G; Gopalsamy A; Herbertz T; Burns CJ; Condon SM
    Bioorg Med Chem Lett; 2010 May; 20(9):2968-73. PubMed ID: 20347591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.